Population Pharmacokinetic Model for Adherence Evaluation Using Lamivudine Concentration Monitoring

被引:13
|
作者
Zhang, Chao [1 ]
Denti, Paolo [1 ]
van der Walt, Jan-Stefan [1 ]
Ren, Yuan [1 ]
Smith, Peter [1 ]
Karlsson, Mats O. [2 ]
McIlleron, Helen [1 ]
机构
[1] Univ Cape Town, Dept Med, Div Clin Pharmacol, ZA-7925 Cape Town, South Africa
[2] Uppsala Univ, Dept Pharmaceut Biosci, Uppsala, Sweden
基金
英国惠康基金;
关键词
lamivudine; population pharmacokinetics; NONMEM; CHILDREN; TUBERCULOSIS; RIFAMPICIN;
D O I
10.1097/FTD.0b013e31825c6067
中图分类号
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号
1001 ;
摘要
Background: Interpretation of antiretroviral drug concentration measurements could be aided by information about adherence to recent doses. We developed a population pharmacokinetic model of lamivudine in young children to propose reference lamivudine concentrations for evaluation of adherence to recent treatment doses. Methods: The steady state pharmacokinetics of lamivudine were evaluated in 68 young HIV-infected children receiving antiretroviral treatment twice daily. A population pharmacokinetic analysis was conducted using NONMEM 7. Results: A 2-compartment model with transit absorption best described lamivudine pharmacokinetics. After adjustment for maturation and body weight (using allometric scaling), the variability of clearance was small, hence simulations could accurately predict lamivudine concentrations. Higher lamivudine trough concentrations were detected before the morning dose, possibly owing to slower overnight clearance. Reference values for lamivudine concentrations that can be used to evaluate adherence to recent doses are proposed. Conclusions: Lamivudine concentration measurement can be used to assess recent treatment adherence.
引用
收藏
页码:481 / 484
页数:4
相关论文
共 50 条
  • [21] Evaluation of Saliva as an Alternative Matrix for Monitoring Plasma Zidovudine, Lamivudine and Nevirapine Concentrations in Rwanda
    Gras, Alain
    Schneider, Serge
    Karasi, Jean-Claude
    Ternes, Anne-Marie
    Sauvageot, Nicolas
    Karasi-Omes, Christine
    Henry, Anne-Pascale
    Schmit, Jean-Claude
    Seguin-Devaux, Carole
    Arendt, Vic
    CURRENT HIV RESEARCH, 2011, 9 (04) : 223 - 228
  • [22] Reconstructing population exposures to acrylamide from human monitoring data using a pharmacokinetic framework
    Lin, Yu-Sheng
    Morozov, Viktor
    Kadry, Abdel-Razak
    Caffrey, James L.
    Chou, Wei -Chun
    CHEMOSPHERE, 2023, 331
  • [23] The Evolution of Population Pharmacokinetic Model of Oral Phenytoin for Early Seizure Prophylaxis Post-craniotomy
    Li, Zhongdong
    Wang, Chuan
    Ji, Shuangmin
    Jin, Hao
    Song, Guiqin
    CURRENT DRUG METABOLISM, 2019, 20 (09) : 756 - 764
  • [24] Optimization of Busulfan Dosing Regimen in Pediatric Patients Using a Population Pharmacokinetic Model Incorporating GST Mutations
    Yuan, Jinjie
    Sun, Ning
    Feng, Xinying
    He, Huan
    Mei, Dong
    Zhu, Guanghua
    Zhao, Libo
    PHARMACOGENOMICS & PERSONALIZED MEDICINE, 2021, 14 : 253 - 268
  • [25] A population pharmacokinetic model to predict oxypurinol exposure in patients on haemodialysis
    Wright, Daniel F. B.
    Doogue, Matthew P.
    Barclay, Murray L.
    Chapman, Peter T.
    Cross, Nicholas B.
    Irvine, John H.
    Stamp, Lisa K.
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2017, 73 (01) : 71 - 78
  • [26] Development of a population pharmacokinetic model of prucalopride in children with functional constipation
    van Schaick, Erno
    Benninga, Marc A.
    Levine, Amy
    Magnusson, Mats
    Troy, Steven
    PHARMACOLOGY RESEARCH & PERSPECTIVES, 2016, 4 (04):
  • [27] Establishment and validation of a population pharmacokinetic model for apatinib in patients with tumors
    Zuo, Li'an
    Ling, Jing
    Hu, Nan
    Chen, Rong
    BMC CANCER, 2024, 24 (01)
  • [28] Population Pharmacokinetic Model for Cancer Chemoprevention With Sulindac in Healthy Subjects
    Berg, Alexander K.
    Mandrekar, Sumithra J.
    Ziegler, Katie L. Allen
    Carlson, Elsa C.
    Szabo, Eva
    Ames, Mathew M.
    Boring, Daniel
    Limburg, Paul J.
    Reid, Joel M.
    JOURNAL OF CLINICAL PHARMACOLOGY, 2013, 53 (04) : 403 - 412
  • [29] Population pharmacokinetic model of PI-88, a heparanase inhibitor
    Hudachek, Susan F.
    Eckhardt, S. Gail
    Hicks, Barbara
    Gustafson, Daniel L.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2010, 65 (04) : 743 - 753
  • [30] Development and Quality Control of a Population Pharmacokinetic Model Library for Caspofungin
    Xu, Nuo
    Shi, Yufei
    Wang, Yixue
    Mak, Wenyao
    Yang, Wenyu
    Ng, Kar Weng
    Wu, Yue
    Tang, Zhijia
    He, Qingfeng
    Yan, Gangfeng
    Xiang, Xiaoqiang
    Zhu, Xiao
    PHARMACEUTICS, 2024, 16 (06)